Carolina González-Abós1, F Borja de Lacy2, Yoelimar Guzmán1, Sara T Nogueira1, Ana Otero-Piñeiro1, Raúl Almenara1, Antonio M Lacy1. 1. Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Advances in Surgery (AIS) Channel, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Centre, Villarroel 170, 08036, Barcelona, Spain. 2. Department of Gastrointestinal Surgery, Institute of Digestive and Metabolic Diseases, Hospital Clinic, IDIBAPS, Advances in Surgery (AIS) Channel, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Centro Esther Koplowitz, and Cellex Biomedical Research Centre, Villarroel 170, 08036, Barcelona, Spain. borjalacy@gmail.com.
Abstract
BACKGROUND: For mid and low rectal cancer, transanal total mesorectal excision (TaTME) has been established as an alternative approach to laparoscopic surgery. However, there are concerns about an unexpected pattern of local recurrence. This study aimed to analyze the pattern of local recurrence for patients treated with TaTME in a tertiary referral center. METHODS: A retrospective single-center analysis was performed. Since 2011, all patients with rectal cancer undergoing TaTME with curative intent were prospectively included in a standardized database. Patients with tumors within 12 cm, clinical stage II or III were included. The primary endpoint of the study was the overall local recurrence rate, together with a critical analysis of the patterns of local failures. RESULTS: Two hundred and five patients were included in this analysis. At the time of surgery, patients had a mean age of 67.1 years (SD 12.3), and 66.8% were male. Neoadjuvant therapy was administered in 73.7%. Mesorectal specimen quality was complete or near-complete in 98.5%, while circumferential resection margin was ≤ 1 mm (including T4 tumors) in 11.8%. After a median follow-up of 34.3 months (95% CI 30.1-38.5), 3.4% (n = 7) presented with local recurrent disease. Six out of the seven patients were also diagnosed with hematogenous metastases. Of the seven patients, three presented with at least one of the following risk factors: T4 tumor, N2 disease, incomplete mesorectal specimen, or positive CRM. Local failure was noted posteriorly (n = 3), laterally (n = 2), anteriorly (n = 1), and in the axial compartment (n = 1). Median time to relapse was 31.5 months (10.3-40.9). The median follow-up after local recurrence was 7.9 (95% CI 6.7-9.1) months, with an overall survival of 85.7%. CONCLUSIONS: TaTME provided satisfactory local recurrence outcomes, and the most common patterns of failure were in the central pelvis.
BACKGROUND: For mid and low rectal cancer, transanal total mesorectal excision (TaTME) has been established as an alternative approach to laparoscopic surgery. However, there are concerns about an unexpected pattern of local recurrence. This study aimed to analyze the pattern of local recurrence for patients treated with TaTME in a tertiary referral center. METHODS: A retrospective single-center analysis was performed. Since 2011, all patients with rectal cancer undergoing TaTME with curative intent were prospectively included in a standardized database. Patients with tumors within 12 cm, clinical stage II or III were included. The primary endpoint of the study was the overall local recurrence rate, together with a critical analysis of the patterns of local failures. RESULTS: Two hundred and five patients were included in this analysis. At the time of surgery, patients had a mean age of 67.1 years (SD 12.3), and 66.8% were male. Neoadjuvant therapy was administered in 73.7%. Mesorectal specimen quality was complete or near-complete in 98.5%, while circumferential resection margin was ≤ 1 mm (including T4 tumors) in 11.8%. After a median follow-up of 34.3 months (95% CI 30.1-38.5), 3.4% (n = 7) presented with local recurrent disease. Six out of the seven patients were also diagnosed with hematogenous metastases. Of the seven patients, three presented with at least one of the following risk factors: T4 tumor, N2 disease, incomplete mesorectal specimen, or positive CRM. Local failure was noted posteriorly (n = 3), laterally (n = 2), anteriorly (n = 1), and in the axial compartment (n = 1). Median time to relapse was 31.5 months (10.3-40.9). The median follow-up after local recurrence was 7.9 (95% CI 6.7-9.1) months, with an overall survival of 85.7%. CONCLUSIONS: TaTME provided satisfactory local recurrence outcomes, and the most common patterns of failure were in the central pelvis.
Authors: Antonio M Lacy; Marta M Tasende; Salvadora Delgado; María Fernandez-Hevia; Marta Jimenez; Borja De Lacy; Antoni Castells; Raquel Bravo; Steven D Wexner; Richard J Heald Journal: J Am Coll Surg Date: 2015-03-30 Impact factor: 6.113
Authors: Martijn Hgm van der Pas; Eva Haglind; Miguel A Cuesta; Alois Fürst; Antonio M Lacy; Wim Cj Hop; Hendrik Jaap Bonjer Journal: Lancet Oncol Date: 2013-02-06 Impact factor: 41.316
Authors: James Fleshman; Megan E Branda; Daniel J Sargent; Anne Marie Boller; Virgilio V George; Maher A Abbas; Walter R Peters; Dipen C Maun; George J Chang; Alan Herline; Alessandro Fichera; Matthew G Mutch; Steven D Wexner; Mark H Whiteford; John Marks; Elisa Birnbaum; David A Margolin; David W Larson; Peter W Marcello; Mitchell C Posner; Thomas E Read; John R T Monson; Sherry M Wren; Peter W T Pisters; Heidi Nelson Journal: Ann Surg Date: 2019-04 Impact factor: 12.969
Authors: Andrew R L Stevenson; Michael J Solomon; John W Lumley; Peter Hewett; Andrew D Clouston; Val J Gebski; Lucy Davies; Kate Wilson; Wendy Hague; John Simes Journal: JAMA Date: 2015-10-06 Impact factor: 56.272
Authors: Sapho Xenia Roodbeen; Antonino Spinelli; Willem Bemelman; Francesca Di Candido; Maylis Cardepont; Quentin Denost; Andre D'Hoore; Susan van Dieren; Bert Houben; Joep J Knol; Beatriz Martín-Pérez; Eric Rullier; Dana Sands; Ilana Setton; Katrien Van de Steen; Pieter J Tanis; Steven D Wexner; Albert M Wolthuis; Roel Hompes Journal: Ann Surg Date: 2021-12-01 Impact factor: 12.969
Authors: Kuo Chen; Jin Zhang; Narasimha M Beeraka; Mikhail Y Sinelnikov; Xinliang Zhang; Yu Cao; Pengwei Lu Journal: J Clin Med Date: 2022-03-25 Impact factor: 4.241